Search in:

Advanced search

OncoTargets and Therapy Volume 11, 2018 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Clinical Trial Report

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

Todd M Bauer1 Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA;2 Medical Oncology, Tennessee Oncology, Nashville, TN, USACorrespondence[email protected]

Manish R Patel1 Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA;3 Medical Oncology, Florida Cancer Specialists, Sarasota, FL, USA

Andres Forero-Torres4 Hematology and Oncology Division, University of Alabama at Birmingham, Birmingham, AL, USA

Thomas J George Jr5 Department of Medicine, University of Florida, Gainesville, FL, USA

Albert Assad6 Biostatistics, Incyte Corporation, Wilmington, DE, USA

Yining Du6 Biostatistics, Incyte Corporation, Wilmington, DE, USA

Herbert Hurwitz7 Department of Medicine, Duke University Medical Center, Durham, NC, USA

show all

Pages 2399-2407 | Published online: 30 Apr 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

ThomasSJSnowdenJAZeidlerMPDansonSJThe role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumoursBr J Cancer2015113336537126151455
PubMed Web of Science ®Google Scholar
Quintás-CardamaAKantarjianHCortesJVerstovsekSJanus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondNat Rev Drug Discov201110212714021283107
PubMed Web of Science ®Google Scholar
CortasTEisenbergRFuPKernJPatrickLDowlatiAActivation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancerLung Cancer200755334935517161498
PubMed Web of Science ®Google Scholar
KomazakiTNagaiHEmiMHypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancersJpn J Clin Oncol200434419119415121754
PubMed Web of Science ®Google Scholar
TamLMcGlynnLMTraynorPMukherjeeRBartlettJMEdwardsJExpression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancerBr J Cancer200797337838317595657
PubMed Web of Science ®Google Scholar
CarsonJABaltgalvisKAInterleukin 6 as a key regulator of muscle mass during cachexiaExerc Sport Sci Rev201038416817620871233
PubMed Web of Science ®Google Scholar
EvansWJMorleyJEArgilésJCachexia: a new definitionClin Nutr200827679379918718696
PubMed Web of Science ®Google Scholar
MondelloPLacquanitiAMondelloSEmerging markers of cachexia predict survival in cancer patientsBMC Cancer20141482825400234
PubMed Web of Science ®Google Scholar
JAKAFI^® (ruxolitinib) [prescribing information]Wilmington, DE, USAIncyte Corporation2016
Google Scholar
JAKAVI^® (ruxolitinib) [summary of product characteristics]Camberley, UKNovartis Europharm Limited2016
Google Scholar
Quintás-CardamaAVaddiKLiuPPreclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood2010115153109311720130243
PubMed Web of Science ®Google Scholar
HurwitzHIUppalNWagnerSARandomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failedJ Clin Oncol201533344039404726351344
PubMed Web of Science ®Google Scholar
ABRAXANE^® (nab-paclitaxel) [prescribing information]Summit, NJ, USACelgene Corporation2015
Google Scholar
GEMZAR^® (gemcitabine) [prescribing information]Indianapolis, IN, USALilly USA2017
Google Scholar
HarrisonCKiladjianJJAl-AliHKJAK inhibition with ruxolitinib versus best available therapy for myelofibrosisN Engl J Med2012366978779822375970
PubMed Web of Science ®Google Scholar
VerstovsekSKantarjianHMesaRASafety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisN Engl J Med2010363121117112720843246
PubMed Web of Science ®Google Scholar
VerstovsekSMesaRAGotlibJA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisN Engl J Med2012366979980722375971
PubMed Web of Science ®Google Scholar
WormannSMSongLAiJLoss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survivalGastroenterology20161511180193.e1227003603
PubMed Web of Science ®Google Scholar
HurwitzHVan CutsemEBendellJCTwo randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2)J Clin Oncol2017354 Suppl34327918718
PubMed Web of Science ®Google Scholar
EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
PubMed Web of Science ®Google Scholar
GoldsteinDEl-MaraghiRHHammelPnab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trialJ Natl Cancer Inst20151072dju41325638248
PubMedGoogle Scholar
Von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
PubMed Web of Science ®Google Scholar
BendellJO’ReillyEMMiddletonMRPhase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancerAnn Oncol201526480481125573533
PubMed Web of Science ®Google Scholar
IkedaMSatoAMochizukiNPhase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabineCancer Sci2016107121818182427685612
PubMed Web of Science ®Google Scholar
SteinSMJamesESDengYFinal analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancerBr J Cancer2016114773774327022826
PubMed Web of Science ®Google Scholar
WadaKSanoKAmanoHBiweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility studyJ Hepatobiliary Pancreat Sci201522969269826136371
PubMed Web of Science ®Google Scholar
YamaueHSatoiSKanbeTPhase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancerCancer Chemother Pharmacol20147319710224146260
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date